To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

A Phase 2, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm, Dose-comparison Trial of OPC-6535 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00917150
• Other study ID #: 197-08-801
• Secondary ID: JapicCTI-090770
• Status: Completed
• Phase: Phase 2
• Start date: March 2009
• Est. completion date: April 2014

Study information

• Verified date: April 2021
• Source: Otsuka Pharmaceutical Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To investigate the efficacy and safety of OPC-6535 in COPD patients, using the measurement of trough FEV1 over time as the primary endpoint.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 771
• Est. completion date: April 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age 40 to 75 years, inclusive, at the time informed consent is obtained
• Ability to provide own written informed consent
• Agree to use an appropriate method of contraception until 3 months after the last dose of the investigational medicinal product (IMP)
• A rating of 1 or higher on the Goddard scale in assessment of emphysema severity by chest CT scan at screening
• Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) of less than 70% at screening
• Cigarette smoking history of at least 20 pack years at screening

Exclusion Criteria:

• Subjects with obstructive disorders due to bronchial asthma
• Subjects receiving long-term oxygen therapy
• Subjects with active tuberculosis or obvious bronchiectasis
• Complication of malignant tumor
• Uncontrolled cardiovascular, endocrine, blood, or nervous system disorders
• Uncontrolled condition with COPD exacerbation of level 2 or 3 within 8 weeks prior to the start of washout period (within 12 weeks prior to start of treatment period)

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• tetomilast (OPC-6535)
oral administration of 12.5mg OPC-6535, once daily for 24months
• tetomilast (OPC-6535)
oral administration of 25mg OPC-6535, once daily for 24months
• tetomilast (OPC-6535)
oral administration of 50 mg OPC-6535, once daily for 24months
• placebo
oral administration of placebo, once daily for 24months

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Otsuka Pharmaceutical Co., Ltd.

Countries where clinical trial is conducted

China,  Japan,  Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Trough Forced Expiratory Volume in 1 Second (FEV1) Change From Baseline to 24 Months	Measurement over time (from baseline over the 24-month treatment period) and change from baseline to end of the treatment period.	Baseline, 24 months
Secondary	Change From Baseline at 24 Months in Total Symptom Diary Score	Subjects were required to keep a symptom diary throughout the entire trial period from the start of investigational medicinal product (IMP) administration in the washout period until the end of the treatment period. Assessment items included scores for shortness of breath, cough, and sputum, IMP compliance, use of salbutamol and respiratory symptom medications, and smoking status. Subjects recorded a score of between 0 and 3, with 0 indicating no symptoms and 3 indicating a high level of symptoms, for each domain.	Baseline, 24 months
Secondary	Change From Baseline at 24 Months in St. George's Respiratory Questionnaire (SGRQ) Total Score	The SGRQ is a self-administered questionnaire designed to measure and quantify the impact of chronic respiratory disease on health-related quality of life (QOL) and well-being in three domains: symptoms, activity, and impact on daily life. The SGRQ was completed by each subject prior to IMP administration at baseline and at Month 6, Month 12, Month 18, and Month 24 (end of treatment).; A weighted score based on population norms for each dimension and total was evaluated. Scores were expressed as a percentage of overall impairment where 100 represented worst possible health status and 0 indicated best possible health status. Scores were calculated when less than 24% of the item scores were missing, otherwise the scores were set to missing. Where there were multiple answers for a question, the worst case was used.	Baseline, 24 months